Empowering chemists through SygDesign platform: Delivering AI solutions at the enterprise level

Artificial intelligence (AI) holds immense potential to transform drug discovery, but adoption in drug discovery is often hindered by complex workflows, integration barriers, and usability challenges. In this poster, Sygnature Discovery presents a novel framework that leverages the Electronic Lab Notebook (ELN) paradigm to standardise and simplify AI-driven drug discovery.

Key Features of Our ELN-Based AI Framework

Our solution is designed to enable medicinal chemists and bench scientists to access and apply cutting-edge AI tools with ease:

• ELN integration of AI workflows for intuitive, protocol-based execution
• User-centric design that empowers chemists to move beyond synthesis and engage directly in compound design
• FAIR-aligned data structure to maximise findability, accessibility, and reusability across discovery projects
• Scalable workflow management to connect diverse datasets and complex discovery tasks

With end-to-end tracking, a modular LIMS, and scalable liquid handling automation, our infrastructure is designed to meet the evolving needs of both internal discovery teams and external collaborators.

Empowering Chemists, Accelerating Discovery

By mirroring the familiar ELN interface, this framework removes barriers to AI adoption, enabling chemists to bring their practical expertise into the design process. The result is faster decision-making, improved compound quality, and maximised ROI on AI investments.

Download the full poster to explore how Sygnature Discovery’s ELN-based AI integration is transforming the way discovery scientists engage with next-generation computational tools.

At Sygnature Discovery, our multidisciplinary teams combine AI, computational chemistry, and lab expertise to deliver smarter, more effective discovery programmes. Speak to our team today to see how we can accelerate your AI-enabled discovery journey.